MX2016003754A - Una composicion farmaceutica estable que contiene amlodipina y valsartan. - Google Patents

Una composicion farmaceutica estable que contiene amlodipina y valsartan.

Info

Publication number
MX2016003754A
MX2016003754A MX2016003754A MX2016003754A MX2016003754A MX 2016003754 A MX2016003754 A MX 2016003754A MX 2016003754 A MX2016003754 A MX 2016003754A MX 2016003754 A MX2016003754 A MX 2016003754A MX 2016003754 A MX2016003754 A MX 2016003754A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
valsartan
stable pharmaceutical
composition containing
containing amlodipine
Prior art date
Application number
MX2016003754A
Other languages
English (en)
Inventor
Jana Salandova
Lucie Krumbholcova
Tereza Varilova
Marketa Pracna
Lenka Kukackova
Ales Bartunek
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of MX2016003754A publication Critical patent/MX2016003754A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a una composición farmacéutica estable que tiene la forma de una tableta monocapa. La composición contiene valsartán, amlodipina o sales farmacéuticamente aceptables de los mismos y por lo menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de acuerdo con la invención puede contener hidroclorotiazida como un ingrediente activo adicional.
MX2016003754A 2013-10-08 2014-10-08 Una composicion farmaceutica estable que contiene amlodipina y valsartan. MX2016003754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2013-783A CZ2013783A3 (cs) 2013-10-08 2013-10-08 Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
PCT/CZ2014/000113 WO2015051771A1 (en) 2013-10-08 2014-10-08 A stable pharmaceutical composition containing amlodipine and valsartan

Publications (1)

Publication Number Publication Date
MX2016003754A true MX2016003754A (es) 2016-07-08

Family

ID=51903736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003754A MX2016003754A (es) 2013-10-08 2014-10-08 Una composicion farmaceutica estable que contiene amlodipina y valsartan.

Country Status (14)

Country Link
EP (1) EP3054925B1 (es)
JP (1) JP2016536285A (es)
KR (1) KR20160058763A (es)
CN (1) CN105579031B (es)
BR (1) BR112016007414A2 (es)
CZ (1) CZ2013783A3 (es)
EA (1) EA201690679A1 (es)
ES (1) ES2689685T3 (es)
IL (1) IL244847A0 (es)
MX (1) MX2016003754A (es)
PT (1) PT3054925T (es)
UA (1) UA119544C2 (es)
WO (1) WO2015051771A1 (es)
ZA (1) ZA201601304B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320903B1 (en) * 2015-07-08 2021-05-19 HK inno.N Corporation Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
CN105853418A (zh) * 2016-05-23 2016-08-17 上海麦步医药科技有限公司 含有左旋氨氯地平和阿齐沙坦的组合物
WO2019008485A1 (en) * 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
CN108567759B (zh) * 2018-07-26 2019-06-04 北京百奥药业有限责任公司 一种缬沙坦氢氯噻嗪片及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN112641743B (zh) * 2020-12-23 2022-09-02 上海耀大生物科技有限公司 一种用于治疗高血压的复方制剂及其制备工艺
CN114917226A (zh) * 2022-03-16 2022-08-19 黄山中皇制药有限公司 一种缬沙坦左氨氯地平组合物
EP4331586A1 (en) * 2022-08-31 2024-03-06 Adamed Pharma S.A. Anticoagulant therapy with an improved dosage regimen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870098A3 (en) 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
JP2011507973A (ja) * 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物

Also Published As

Publication number Publication date
CN105579031B (zh) 2018-12-11
ZA201601304B (en) 2017-05-31
ES2689685T3 (es) 2018-11-15
KR20160058763A (ko) 2016-05-25
JP2016536285A (ja) 2016-11-24
EP3054925B1 (en) 2018-07-04
EP3054925A1 (en) 2016-08-17
IL244847A0 (en) 2016-05-31
PT3054925T (pt) 2018-10-30
WO2015051771A1 (en) 2015-04-16
UA119544C2 (uk) 2019-07-10
CN105579031A (zh) 2016-05-11
BR112016007414A2 (pt) 2017-08-01
CZ2013783A3 (cs) 2015-04-15
EA201690679A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
PH12015501096A1 (en) Composition for immediate and extended release
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
MX359288B (es) Forma iv del clorhidrato de ivabradina.
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
GEP20135859B (en) Stable combined pharmaceutical composition
TR201102067A1 (tr) Valsartan ve amlodipin kombinasyonları.
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
MY194591A (en) Pharmaceutical combination formulation
IN2013MU03656A (es)